Evidence map›Paper›PMID 9155042›Full record

ArticleBritish journal of cancer1997

Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis.

L Bjørge, S Junnikkala, E K Kristoffersen, J Hakulinen, R Matre, S Meri

Open access · greenAbstract read
In one paragraph

Article in British journal of cancer, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2016
    Article
  5. Article
  6. Article
  7. Ascitic complement system in ovarian cancer.British journal of cancer · 2005
    Article
  8. Article
  9. Complement-mediated killing of microtumors in vitro.The American journal of pathology · 1998
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

L BjørgeDepartment of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Finland.
S Junnikkala
E K Kristoffersen
J Hakulinen
R Matre
S Meri
University of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1 cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in three-dimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement.

Indexed as

Cytotoxicity, ImmunologicAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityAntigens, CDCD55 AntigensCD59 AntigensComplement ActivationComplement Inactivator ProteinsComplement System ProteinsFemaleFlow CytometryFluorescent Antibody Technique, IndirectHumansMembrane Cofactor ProteinMembrane GlycoproteinsOvarian NeoplasmsAntibodies, MonoclonalAntigens, CDCD46 protein, humanCD55 AntigensCD59 AntigensComplement Inactivator ProteinsComplement System ProteinsMembrane Cofactor ProteinMembrane Glycoproteins

Identifiers

PMID9155042
PMCPMC2228228
OpenAlexW2001315042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.